Agenus Shares Are Trading Lower. The Company Announced Updated Results From Its Phase 1 Clinical Trial of BOT/BAL Combination Therapy in Patients With Metastatic CRC That Is Not Microsatellite Instability-high or Deficient Mismatch Repair
Agenus 股價走低。該公司公佈了其針對轉移性結直腸癌患者的BOT/BAL聯合療法的1期臨床試驗的最新結果,這些患者不是微衛星不穩定性(高度或缺陷的錯配修復)